Preeclampsia (PE) is characterized by hypertension and proteinuria after the 20th gestational week (GW). It is a and mortality during pregnancy. There is increasing evidence suggesting that PE is due to an impaired balance between maternal placental angiogenic and antiangiogenic factors that harm maternal vascular endothelium. The study aimed into practice the soluble fms-like tyrosine kinase (sFlt-1) to placental growth factor (PlGF) ratio test to improve the management of preeclampsia and adverse pregnancy outcome, intrauterine growth retardation, iatrogenic prematurity, and placental abruption. We report a case study in which we used the sFlt-1/PlGF ratio in the management of a high-risk pregnancy. Unnecessary hospitalization was avoided, and the patient was managed appropriately.
Introduction
Preeclampsia (PE) is characterized by hypertension and proteinuria after the 20th gestational week (GW) and is a major cause of maternal, perinatal morbidity, and mortality during pregnancy [1] . The incidence on a global scale is subject to discussions, but it has 2 and 8% of all pregnancies [2] . Forty-two percent of all maternal preterm deliveries are correlated to PE [2] . According to Shennan et al., sub-standard care accounts for 20 out of 22 lethal outcomes, which are undoubtedly avoidable [3] . PE was divided into early -before the 34th gestational week, and late -after the 34th gestational week [1] .
of the etiology and pathogenesis of preeclampsia, therapeutic means for treatment. The pathogenesis of PE is still not well understood, regardless of the enormous number of researches [2] . It is clear that the condition Case Report Vasileva P, et al. ...
originates from the placenta, and its target is the maternal endothelium [4, 5] . We present a case of a 30-year-old tertiparous woman at high-risk for developing severe preeclampsia, in which we used the sFlt-1/PlGF ratio for the optimal management of the pregnancy.
Case description
We present a 30-year-old patient with a third pregnancy and second parturition. She did not report any concomitant diseases. She was overweight with a body mass index 29. Her parturition of a dead hypotrophic fetus with a bodyweight of 2000 grams (g), in the 38th (+2) gestation week. At the moment of parturition, her blood pressure raised to 180/110 mm Hg, and proteinuria of 0.6 g/l was found. Paraclinical parameters and blood pressure had not been followed during pregnancy.
in the uterine arteries was found during her second pregnancy, assessed by the pulsatility index, with the presence of bilateral notching bilaterally on Doppler ultrasound, on a visit for antenatal assessment of the fetal morphology in the second trimester (20th gestational week). After that, the patient visited the Department of Pregnancy Pathology every month for evaluation of her status and the condition of the fetus. Her blood pressure reached nearly 150/100 mm Hg since the 29th gestational week and proteinuria of up to 0.3 g/l. Antihypertensive medication was prescribed. Correction of hypoalbuminemia was performed at the time of parturition. Blood pressure of up to 170/110 mm Hg was found. The patient delivered a live fetus with a bodyweight of 2900 g in 38th (+0) gestational week. She was pregnant in 20th (+1) gestational for evaluation of fetal anatomy in the second trimester. The blood pressure at this moment was normal. One eutrophic fetus of female gender was found on examination, with normal fetal anatomy. On Doppler examination of the uterine arteries, highly increased resistance was found bilaterally, with the presence of notching on the right side uterine artery pulsatility index (UTPI) -1.68, uterine artery resistance index (UTRI) -0.83; on the left side UTPI -2.4, UTRI -0.74; with bilateral notching. The patient was followed up on an out-patient basis, and her blood pressure was checked. Test strips were used for checking proteinuria. The sFlt-1, PlGF, and sFlt-1/PlGF ratios were examined twice during the pregnancy by immunological test the second trimester (22nd GW), and the second sample was taken at the beginning of the third trimester of the pregnancy ( 28 th GW). The two of 38. (Table 1) . She was not hospitalized during this pregnancy until going into labor. The pregnancy ended with the parturition of a live fetus with a bodyweight of 3130 g in 39th (+0) gestational week. The blood pressure was within the normal range. The urinary test was normal.
Discussion
Hypertensive abnormalities during pregnancy are the third leading cause of maternal mortality after hemorrhage and infectious complications. Placental dysfunction and the associated complications account for 18% of the lethal outcomes of parturient women in the world. The incidence of PE on a global scale is a subject of discussions, but in the last few years, it is estimated explicitly accepted screening model for early still does not exist. The management of PE is [6, 7] .
Several markers were studied for Since it is now clear that PE represents a form of placental dysfunction, attempts are undertaken for introducing the sFlt-1/PlGF ratio in the prediction, diagnosis, and prognosis for PE development. The ratio of sFlt-1/PlGF can become a fundamental tool in overcoming of preeclampsia, especially as an automatic test, which allows for rapid and easy measurement of these markers [8] . The ratio of serum fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) has diagnostic value, and this ratio test for preeclampsia, the Elecsys® sFlt-1/PlGF immunoassay ratio (Roche Diagnostics GmbH, Mannheim, Germany) [9, 10] .
Having in mind the obstetrical medical history for two previous pregnancies with preeclampsia, and highly increased resistance in the uterine arteries, our patient was highly suspected for developing PE and adverse outcome of the pregnancy. That is why, during the previous pregnancy, the woman was hospitalized monthly at the Department of Pregnancy Pathology for assessment. This approach, however, was current pregnancy, a decision was made for the assessment and management of the patient by using sFlt-1/PlGF immunoassay ratio during the second trimester of pregnancy. Based on the results from the ratio, the values of which patient was observed on an out-patient basis. The pregnancy outcome was normal.
Conclusions
We used the sFlt-1/PlGF ratio test into clinical practice to manage high risk for severe PE. Based on the low rates of the ratio measured twice during the second trimester of pregnancy, we managed the pregnancy appropriately without unnecessary hospitalization. Further studies are necessary for the assessment of the possibilities of sFlt-1/PlGF ratio test in the prediction, diagnosis, and prognosis of preeclampsia.
